Form 10-Q Adverum Biotechnologies, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Adverum Biotechnologies (ADVM) PT Lowered to $10 at RBC Capital
November 5, 2024 6:57 AM ESTRBC Capital analyst Luca Issi lowered the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $10.00 (from $12.00) while maintaining a Sector Perform rating.
The analyst comments "ADVM reported 3Q24 results and updated timelines for the next LUNA readout (52-week results now anticipated... More
